Attomarker is delighted to be invited to India at the opening of “Superbugs. The End of Antibiotics?” exhibition in Delhi on 6th September 2019. The exhibition is being formally opened by India’s Health Minister, Harsh Vardhan.
India has taken huge strides to tackle antibiotic resistance, with the Chennai declaration and most recently the ban on the use of colistin for animal use. The Indian Government through the Biotechnology Industry Research Assistance Council ( BIRAC ), have invested heavily in supporting new biotech companies develop solutions in this space.
Ahead of the Superbugs exhibition opening, the Longitude Prize and BIRAC are hosting a Diagnostic Roundtable
seminar , built around diagnostic tests which help guide antibiotic prescribing, some of which appear in the exhibition.
Nesta Challenges , the organisation that is running the Longitude Prize, has invited Professor Andrew Shaw of the University of Exeter, founder and CEO of Attomarker, to present the Attomarker diagnostic device which is designed to discriminate between viral and bacterial conditions, thus reducing unnecessary antibiotic prescription.
The World Health Organisation recently declared that “the rise of antimicrobial resistance is a global crisis, recognised as one of the greatest threats to health today. With few replacement products in the R&D pipeline, the world is heading to a post-antibiotic era in which common infections will once again kill”.
Later this year, Attomarker will be at the Superbugs Exhibition associated with the General Assembly of the United Nations in New York.
Professor Andrew Shaw is CEO & Founder of Attomarker ( firstname.lastname@example.org ) , a spin-out company from the University of Exeter, which has developed a multiplex blood-testing device which can give results in five minutes from a tiny finger-tip blood sample. More at www.attomarker.com. Prof Shaw is Associate Professor of Physical Chemistry.